Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Consensus Rating of “Buy” from Brokerages

Posted by Brenda Bartman on Oct 2nd, 2026

Definium Therapeutics, Inc. (NASDAQ:DFTX – Get Free Report) has been assigned an average recommendation of “Buy” from the twenty-one ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eighteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $64.88.

A number of equities analysts have issued reports on DFTX shares. Wall Street Zen cut shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Needham & Company LLC reissued a “buy” rating and issued a $66.00 target price on shares of Definium Therapeutics in a research note on Monday, September 14th. Canaccord Genuity Group set a $78.00 target price on Definium Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Friday, July 17th. Finally, Robert W. Baird upped their price target on Definium Therapeutics from $75.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, September 15th.

View Our Latest Report on Definium Therapeutics

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $37.60 on Friday. The firm has a market cap of $5.05 billion, a PE ratio of -10.96 and a beta of 2.19. Definium Therapeutics has a fifty-two week low of $10.46 and a fifty-two week high of $49.70. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The business has a 50 day moving average price of $41.15 and a 200-day moving average price of $32.34.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Equities research analysts predict that Definium Therapeutics will post -3.02 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Robert Barrow sold 31,550 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the transaction, the chief executive officer directly owned 2,213,090 shares of the company’s stock, valued at approximately $80,932,701.30. The trade was a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of the company’s stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $123,496.89. Following the transaction, the chief financial officer owned 394,528 shares of the company’s stock, valued at approximately $14,427,888.96. This represents a 0.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 71,098 shares of company stock valued at $2,626,115 in the last 90 days. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DFTX. Avoro Capital Advisors LLC bought a new stake in Definium Therapeutics in the fourth quarter worth $66,950,000. Wellington Management Group LLP bought a new position in shares of Definium Therapeutics during the second quarter valued at $138,755,000. Seven Fleet Capital Management LP bought a new position in shares of Definium Therapeutics during the second quarter valued at $6,992,000. Royce & Associates LP raised its position in shares of Definium Therapeutics by 102.5% in the 4th quarter. Royce & Associates LP now owns 164,041 shares of the company’s stock worth $2,197,000 after purchasing an additional 83,017 shares during the last quarter. Finally, Platinum Investment Management Ltd. purchased a new position in shares of Definium Therapeutics in the 4th quarter worth about $937,000. 27.91% of the stock is currently owned by institutional investors.

Definium Therapeutics Company Profile

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.